Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: Data from the Canadian Scleroderma Research Group

Journal of Rheumatology

Volumn 40, Issue 4, 2013, Pages 447-454

  Mansour, Samah ^a,b   Bonner, Ashley ^a,c   Muangchan, Chayawee ^a,d   Hudson, Marie ^e   Baron, Murray ^e   Pope, Janet E ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ST JOSEPH S HEALTH CENTRE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MAHIDOL UNIVERSITY   (Thailand)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Disease activity; Disease severity; Education; Mortality; Socioeconomic status; Systemic sclerosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE; AGED; ARTHRITIS; ARTICLE; CANADIAN SCLERODERMA RESEARCH GROUP; COHORT ANALYSIS; DISEASE DURATION; ECHOCARDIOGRAPHY; EDUCATIONAL STATUS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED VITAL CAPACITY; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE ORGANIZATION; HUMAN; INCOME; LOWEST INCOME GROUP; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; SEX DIFFERENCE; SOCIOECONOMICS; SURVIVAL; SYSTEMIC SCLEROSIS; WORK DISABILITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; COHORT STUDIES; EDUCATIONAL STATUS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; REGISTRIES; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS;

EID: 84875860763     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120570     Document Type: Article

References (60)

1. Goldman DP, Smith JP. Can patient self-management help explain the SES health gradient? Proc Natl Acad Sci USA 2002; 99:10929-34.
2. Saha SK, Saha S, Shakur S, Hanif M, Habib MA, Datta SK, et al. Community-based cross-sectional seroprevalence study of hepatitis A in Bangladesh. World J Gastroenterol 2009;15:4932-7.
3. Avendano M, Kunst AE, Huisman M, Lenthe FV, Bopp M, Regidor E, et al. Socioeconomic status and ischemic heart disease mortality in 10 western European populations during the 1990s. Heart 2006;92:461-7.
4. Tang M, Chen Y, Krewski D. Gender-related differences in the association between socioeconomic status and self-reported diabetes. Int J Epidemiol 2003;32:381-5.
5. Braaten T, Weiderpass E, Lund E. Socioeconomic differences in cancer survival: The Norwegian Women and Cancer Study. BMC Public Health 2009;9:178.
6. Szanton SL, Seplaki CL, Thorpe RJ Jr, Allen JK, Fried LP. Socioeconomic status is associated with frailty: The Women's Health and Aging Studies. J Epidemiol Community Health 2010;64:63-7.
7. Wang MC, Kim S, Gonzalez AA, MacLeod KE, Winkleby MA. Socioeconomic and food-related physical characteristics of the neighborhood environment are associated with body mass index. J Epidemiol Community Health 2007;61:491-8.
8. Fored CM, Ejerblad E, Fryzek JP, Lambe M, Lindblad P, Nyrén O, et al. Socio-economic status and chronic renal failure: A population-based case-control study in Sweden. Nephrol Dial Transplant 2003;18:82-8.
9. Alarcón GS, Calvo-Alén J, McGwin G Jr, Uribe AG, Toloza SM, Roseman JM, et al; LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 2006;65:1168-74.
10. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum 1995;38:274-83.
11. Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma prevalence: Demographic variations in a population-based sample. Arthritis Rheum 2009;6:400-4.
12. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-5.
13. Kernéis S, Boëlle PY, Grais RF, Pavillon G, Jougla E, Flahault A, et al. Mortality trends in systemic sclerosis in France and USA, 1980-1998: An age-period-cohort analysis. Eur J Epidemiol 2010;25:55-61.
14. Winkleby MA, Jatulis DE, Frank E, Fortmann SP. Socioeconomic status and health: How education, income, and occupation contribute to risk factors for cardiovascular disease. Am J Public Health 1992;82:816-20.
15. Braveman PA, Cubbin C, Egerter S, Chideya S, Marchi KS, Metzler M, et al. Socioeconomic status in health research: One size does not fit all. JAMA 2005;294:2879-88.
16. Rodriguez E. Keeping the unemployed healthy: The effect of means-tested and entitlement benefits in Britain, Germany, and the United States. Am J Public Health 2001;91:1403-11.
17. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
18. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
19. Valentini G, D'Angelo S, Della Rossa A, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score [letter]. Ann Rheum Dis 2003;62:904-5.
20. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003;21 Suppl:S39-41.
21. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21 Suppl:S42-6.
22. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
24. Mukerjee D, St. George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: Application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
25. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803-9.
26. Steen VD, Owens GR, Fino GJ, Rodnan GP, Medsger TA Jr. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985;28:759-67.
27. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
28. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008;58:284-91.
29. Groen H, Wichers G, ter Borg EJ, van der Mark TW, Wouda AA, Kallenberg CG. Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. Am J Med 1990;89:34-41.
30. Shanmugam VK, Steen VD. Renal disease in scleroderma: An update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 2012;24:669-76.
31. Fransen J, Popa-Diaconu D, Hesselstrand R, Carreira P, Valentini G, Beretta L, et al. Clinical prediction of 5-year survival in systemic sclerosis: Validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis 2011;70:1788-92.
32. Muangchan C, Harding S, Khimdas S, Bonner A; Canadian Scleroderma Research group, Baron M, et al. Association of C-reactive protein with high disease activity in systemic sclerosis: Results from the Canadian Scleroderma Research Group. Arthritis Care Res 2012;64:1405-14.
33. Cuomo G, Zappia M, Abignano G, Iudici M, Rotondo A, Valentini G. Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology 2009;48:1414-7.
34. Elhai M, Guerini H, Bazeli R, Avouac J, Freire V, Drapé JL, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res 2012;64:1244-9.
35. Sutcliffe N, Clarke AE, Gordon C, Farewell V, Isenberg DA. The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology 1999;38:1130-7.
36. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47-56.
37. Alarcón GS, McGwin G Jr, Sanchez ML, Bastian HM, Fessler BJ, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. Arthritis Rheum 2004;51:73-7.
38. Alarcón GS, Roseman J, Bartolucci AA, Friedman AW, Moulds JM, Goel N, et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1173-80.
39. Alarcón GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001;44:2797-806.
40. Bae SC, Hashimoto H, Karlson EW, Liang MH, Daltroy LH. Variable effects of social support by race, economic status, and disease activity in systemic lupus erythematosus. J Rheumatol 2001;28:1245-51.
41. Czirjak L, Nagy Z, Szegedi G. Survival analysis of 118 patients with systemic sclerosis. J Intern Med 1993;234:335-7.
42. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
43. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750-5.
44. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
45. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
46. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, et al; GENISOS Study Group. Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001;30:332-46.
47. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57:318-26.
48. Nietert PJ, Silver RM, Mitchell HC, Shaftman SR, Tilley BC. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005; 32:1888-92.
49. Kazantseva M, Highton J, Stamp LK, Hessian PA. Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis. Arthritis Res Ther 2012;14:R208.
50. Chaudhary P, Chen X, Assassi S, Gorlova O, Draeger H, Harper BE, et al. Cigarette smoking is not a risk factor for systemic sclerosis. Arthritis Rheum 2011;63:3098-102.
51. Khimdas S, Harding S, Bonner A, Zummer B, Baron M, Pope J; Canadian Scleroderma Research Group. Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry. Arthritis Care Res 2011;63:142-9.
52. Simeon CP, Armadans L, Fonollosa V, Vilardell M, Candell J, Tolosa C, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56:723-8.
53. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-5.
54. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28:2454-9.
55. Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French Itiner AIR-Sclerodermie study. Rheumatology 2009;48:304-8.
56. Joven BE, Almodovar R, Carmona L, Carreira PE. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: Results from a single university hospital. Semin Arthritis Rheum 2010;39:285-93.
57. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
58. Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59-63.
59. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269-77.
60. Kim J, Park SK, Moon KW, Lee EY, Lee YJ, Song YW, et al. The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol 2010;29:297-302.